Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A-Reference-Cited by-同舟云学术

Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A

Published:2020-04-27 Issue:3 Volume:26 Page:478-486
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Motwani Jayashree¹,Guillet Benoit²,Blatny Jan³,Schilling Freimut H.⁴,Wibaut Bénédicte⁵,Goldstine Jimena⁶,Nagy Andras⁷,Doralt Jennifer⁷,Engl Werner⁷,Tangada Srilatha⁶,Spotts Gerald⁶

Affiliation:

1. Birmingham Children's Hospital Birmingham UK

2. IRSET Rennes University Hospital and Inserm U1085 Rennes France

3. Children's University Hospital Brno Brno Czech Republic

4. Luzerner Kantonsspital Lucerne Switzerland

5. CRTH Institut Coeur Poumon CHU Lille France

6. Baxalta US Inc., a member of the Takeda group of companies Lexington MA USA

7. Baxalta Innovations GmbH, a member of the Takeda group of companies Vienna Austria

Funder

Baxalta Innovations GmbH, a Takeda company, Vienna, Austria

Baxalta US Inc., a Takeda company, Westlake Village, CA, USA

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13997

Reference22 articles.

1. Anti‐hemophilic factor (recombinant), plasma/albumin‐free method (octocog‐alpha; ADVATE) in the management of hemophilia A;Shapiro AD;Vasc Health Risk Manag,2007

2. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

3. European Medicines Agency.ADVATE. Summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/advate‐epar‐product‐information_en.pdf. Accessed February 28 2019.

4. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia